Center for Translational Science, Children's National Health System, 111 Michigan Avenue, NW, Washington, DC, 20010, USA.
Department of Medicine, Division of Renal Diseases and Hypertension, The George Washington University School of Medicine and Health Sciences, Walter G. Ross Hall, Suite 738, 2300 I Street, NW, Washington, DC, 20052, USA.
Pharmacogenomics J. 2019 Aug;19(4):315-336. doi: 10.1038/s41397-019-0082-4. Epub 2019 Feb 6.
Hypertension is the most prevalent cause of cardiovascular disease and kidney failure, but only about 50% of patients achieve adequate blood pressure control, in part, due to inter-individual genetic variations in the response to antihypertensive medication. Significant strides have been made toward the understanding of the role of reactive oxygen species (ROS) in the regulation of the cardiovascular system. However, the role of ROS in human hypertension is still unclear. Polymorphisms of some genes involved in the regulation of ROS production are associated with hypertension, suggesting their potential influence on blood pressure control and response to antihypertensive medication. This review provides an update on the genes associated with the regulation of ROS production in hypertension and discusses the controversies on the use of antioxidants in the treatment of hypertension, including the antioxidant effects of antihypertensive drugs.
高血压是心血管疾病和肾衰竭的最常见病因,但只有约 50%的患者实现了充分的血压控制,部分原因是个体对抗高血压药物反应的遗传差异。在理解活性氧 (ROS) 在心血管系统调节中的作用方面已经取得了重大进展。然而,ROS 在人类高血压中的作用仍不清楚。一些参与 ROS 产生调节的基因的多态性与高血压有关,表明它们可能对血压控制和对抗高血压药物的反应有影响。本综述提供了与高血压中 ROS 产生调节相关的基因的最新信息,并讨论了抗氧化剂在高血压治疗中的应用的争议,包括降压药物的抗氧化作用。